Skip to main content
Microbix Biosystems Inc. logo

Microbix Biosystems Inc. — Investor Relations & Filings

Ticker · MBX ISIN · CA59501P1045 TSX Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2026-05-14 Earnings Release
Country CA Canada
Listing TSX MBX

About Microbix Biosystems Inc.

https://microbix.com/

Microbix Biosystems Inc. develops and commercializes proprietary biological and technological solutions for human health, specializing in infectious disease diagnostics. The company is a commercial-scale producer of infectious disease antigens, which are utilized as key ingredients in manufacturing diagnostic tests and for vaccine research and development. Microbix also provides a comprehensive portfolio of external quality control materials (EQC), marketed as Quality Assessment Products (QAPs™). These whole-workflow, multi-analyte controls, available in liquid and swab formulations for IVD and Research Use Only (RUO) applications, support clinical laboratory proficiency testing and assay development across various infectious disease panels, including respiratory, STI, HPV, and gastrointestinal pathogens. The company is ISO 9001 and 13485 accredited, serving the global diagnostics industry.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Earnings Release Classification · 95% confidence The document is a corporate press release titled “Microbix Reports Results for H1 & Q2 2026” that provides the company’s quarterly and half-year financial results, revenue figures, margins, expenses, net loss, and management discussion. It is not a full interim report with audited financial statements or a notice linking to an external report, but rather an earnings announcement summarizing key financial highlights. This matches the definition of an Earnings Release (ER). H1 2026
2026-05-14 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 92% confidence The document is a Form 52-109F2 “Certification of Interim Filings” signed by the CEO, attesting to the accuracy of the interim financial report and MD&A for Q1 2026. It contains no substantive financial data itself but is an officer certification letter. Under the certification rule, such documents are classified as Regulatory Filings (RNS).
2026-05-14 English
News release - English.pdf
Regulatory Filings
2026-05-07 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings
2026-05-06 English
News release - English.pdf
Regulatory Filings
2026-04-27 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the release of podcast episodes featuring discussions with industry experts. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed financial or operational reports. It is primarily a corporate communication about a media initiative (podcast) and includes forward-looking statements. The document length is 6898 characters, which is relatively short and does not contain any financial report or regulatory filing content. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general Regulatory Filing (RNS) as a miscellaneous announcement that does not fit other categories.
2026-04-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.